Formulation and Characterization of Proniosomal Teneligliptin Tablets

Teneligliptin is a BCS class-II anti-diabetic drug having poor solubility and lesser bioavailability. This study aimed to prepare and evaluate the proniosomal powders of Teneligliptin and compress them into tablets to improve the solubility and enhance bioavailability. Free-flowing proniosomal powders of Teneligliptin were prepared by using the slurry method, and maltodextrin was used as a carrier. A total of six Teneligliptin Proniosomal formulations were prepared with various concentrations of cholesterol, span, tween, and soya lecithin. All the prepared formulations were evaluated for, FT-IR analysis, % Entrapment efficiency, In-vitro drug release studies, Vesicle size analysis, and Scanning electron microscopy. Among all the formulations, proniosomal formulation 2(PF2) was found to exhibit the best results for all the evaluation tests, and In vitro drug release was found to be 99.56% at the end of the 24th hour. The proniosomal powder was evaluated for Micromertic properties. The proniosomal powder of the PF2 was successively compressed into a tablet by using the direct compression method. The compressed tablets were characterized for weight variability, friability, hardness, drug content uniformity, and dissolution properties. The dissolution data obtained for the proniosomal teneligliptin tablet were fitted with various release kinetic equations, and the release followed zero-order kinetics.The Proniosomal tablets are a promising approach for Teneligtiptin to overcome the solubility and to increase the drug bioavailability. Overall, the importance of proniosomal tablets is found in their ability to optimize drug delivery, improve patient outcomes, and enhance the overall effectiveness of therapeutic agents.